このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PW Medtech Group バランスシートの健全性

財務の健全性基準チェック /66

PW Medtech Groupの総株主資本はCN¥4.8B 、総負債はCN¥0.0で、負債比率は0%となります。総資産と総負債はそれぞれCN¥5.2BとCN¥327.1Mです。 PW Medtech Groupの EBIT はCN¥191.8Mで、利息カバレッジ比率-4.4です。現金および短期投資はCN¥1.6Bです。

主要情報

負債資本比率

CN¥0

負債

インタレスト・カバレッジ・レシオ	-4.4x
現金	CN¥1.59b
エクイティ	CN¥4.82b
負債合計	CN¥327.06m
総資産	CN¥5.15b

財務の健全性に関する最新情報

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Nov 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Recent updates

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

Feb 18

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

Jan 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

Dec 10

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Nov 22

財務状況分析

短期負債: 1358の短期資産 ( CN¥2.0B ) が短期負債 ( CN¥149.3M ) を超えています。

長期負債: 1358の短期資産 ( CN¥2.0B ) が長期負債 ( CN¥177.8M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 1358は負債がありません。

負債の削減: 1358負債比率が12.6%であった 5 年前と比べて負債がありません。

債務返済能力: 1358には負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: 1358には負債がないため、利息支払いの負担は問題になりません。

PW Medtech Group バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Recent updates

Upcoming dividend of HK$0.05 per share

Executive Chairman & CEO recently sold HK$53k worth of stock

Here's Why PW Medtech Group Limited's (HKG:1358) CEO Might See A Pay Rise Soon

PW Medtech Group Limited (SEHK:1358) announces an Equity Buyback for HKD 150 million worth of its shares.

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Upcoming dividend of HK$0.049 per share at 11% yield

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director Xingdong Zhang has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

New 90-day low: HK$0.52

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

New 90-day high: HK$2.31

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

New 90-day high: HK$2.29

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Market bids up stock over the past week

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

New 90-day high: HK$1.76

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /66